Palatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin 4 ...

Inc. (NYSE American: PTN) has announced the completion of their Phase 2 clinical trial for an obesity treatment, marking a ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

The study's primary endpoint was to evaluate the efficacy of bremelanotide combined with tirzepatide in reducing body weight. Data from this trial are expected later this quarter. The results from ...

"We are poised for a transformational and defining year in 2025, focusing on reporting the topline data of our Phase 2 BMT-801 clinical study evaluating the co-administration of bremelanotide with ...

新泽西州CRANBURY - Palatin Technologies, Inc. (NYSE American: PTN) 宣布完成其肥胖治疗二期临床试验，这标志着开发潜在新疗法的关键一步。该研究名为BMT-801，测试了MC4R bremelanotide和GLP-1/GIP ...

The primary endpoint of the Phase 2 BMT-801 clinical trial is to demonstrate the safety and efficacy of co-administration of bremelanotide with tirzepatide on reducing body weight. Patients were ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.